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COVID-19 and Opioid Use in Appalachian Kentucky: Challenges and Silver Linings
Abstract
Appalachian Kentucky is currently fighting two public health emergencies – COVID-19 and the opioid
epidemic – leaving the area strapped for resources to care for these ongoing crises. During this time,
people who use opioids (PWUO) have increased vulnerability to fatal overdoses and drug-related harms
(e.g., HIV). Disruption of already limited services posed by COVID-19 could have an especially detrimental
impact on the health of PWUO. Though the COVID-19 pandemic is jeopardizing hard-won progress in
fighting the opioid epidemic, innovations in state policy and service delivery brought about by the
pandemic may improve the health of PWUO long-term if they are retained.
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A

ppalachian Kentucky is currently fighting two public health emergencies
—COVID-19 and the decades-long opioid epidemic—leaving the area
strapped for resources to care for two ongoing crises. During this time,
people who use opioids have increased vulnerability to fatal overdoses, lifethreatening withdrawal, relapse, and drug-related harms, such as HIV and
hepatitis C (HCV) infection. Indeed, there is significant evidence that the number
of opioid overdoses in Kentucky has risen since the start of the pandemic.1
Further, access to needed substance-use treatment and harm-reduction services
in the region was limited even before COVID-19, and the very existence of many
of these services was tenuous due to funding constraints and stigma.2,3
Disruption of these already strained services posed by COVID-19 and COVIDrelated public health measures could have an especially detrimental impact on
the health of people who use opioids in Appalachian Kentucky.
The COVID pandemic and resulting economic and social impacts has led to
deleterious effects on mental health in the general population including
increased levels of stress, anxiety, and depression.4–8 These factors can
contribute to the risk of opioid initiation, relapse, and overdose death. Further,
due to stay-at-home orders and social distancing practices, individuals may be
using opioids in isolation more often—a risk factor for fatal overdose given the
limit to bystander’s ability to administer naloxone and/or call emergency
services.1,9
As the novel coronavirus has surged across the globe, it has had a ripple effect
on the international illicit drug supply chain, from production to destination
markets. This disruption can increase the vulnerability of people who use opioids
to drug-related harms such as elevated risk of fatal overdose and HIV/HCV. For
example, closed borders and restricted travel have interrupted the heroin supply
from Mexico to the U.S.10 There are worldwide reports of drug shortages,
reduction in purity, and increased prices.10 Further, widespread COVID-19–
related unemployment has caused economic instability potentially impacting
risk of relapse due to associated stress, risk of withdrawal related to affordability
of drugs, and increased risk behavior related to drug-seeking (i.e., transactional
sex for money and drugs). Alternatively, limited access may actually drive people
who use opioids to seek treatment.
In Kentucky, where 20 of the state’s 54 Appalachian
service program as of September 2020,11 the impact
scale-up and utilization remains largely unknown.
regional health department directors indicate that
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steady or has increased, but programs have needed to adapt to COVID-19 by
moving services outside and shortening the duration of staff–client interactions.
The consequences of more rapid staff–client interactions are currently unclear;
the changes could have heterogeneous impacts across communities and among
clients. On the one hand, the more rapid, lower threshold access to the program
may improve utilization. On the other hand, the brief encounter may prevent
staff from talking with clients about HIV/HCV risk reduction, safe injection
practices, substance-use treatment, and other client needs.
Although the negative effects of the COVID-19 pandemic are vast, loosened
regulations and policies enacted primarily to reduce the community
transmission of COVID-19, may have actually improved access for people who
use opioids to certain services like telehealth for medication for opioid-use
disorder12 and unemployment benefits.13 In March 2020, SAMHSA (Substance
Abuse and Mental Health Services Administration) relaxed the in-person
examination requirement for buprenorphine initiation, allowing authorized
practitioners to utilize telehealth.14 At the beginning of the pandemic, Kentucky’s
governor authorized early releases from jail for nearly 700 inmates held for
nonviolent offenses,15 a positive move to protect incarcerated individuals,
although it also confers an overdose risk particularly if services are not available
to assist these individuals in community re-entry.
Overall, the COVID-19 pandemic is jeopardizing hard-won progress in fighting
the opioid epidemic in Appalachian Kentucky. Although the prevalence of
COVID-19 has been relatively low in the area, a surge in infections could be
disastrous for people who use opioids and the services on which they rely. These
individuals are at a heightened risk for severe illness if they contract COVID-19
because of the immunosuppressive properties of opioids.16 Those who sustain
COVID-related sequelae, particularly compromised lung function, are at
increased risk of fatal overdose due to respiratory depression.9 However,
innovations in state policy and service delivery brought about by COVID-19 (e.g.,
low-threshold access to harm reduction, telehealth for opioid-use disorder
treatment, decarceration) may improve the health of people who use opioids longterm if they are retained beyond the pandemic.
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